Please provide your email address to receive an email when new articles are posted on . A 0.5 mg daily dose of oral dutasteride was superior to minoxidil and finasteride in total hair count at 24 ...

The purpose of this study was to determine the effect of dutasteride on quality of life of men with lower urinary tract symptoms associated with enlarged prostate or benign prostatic hyperplasia (BPH) ...

Objective: The purpose of this study was to examine the rates of acute urinary retention (AUR) and surgery after initiating 5-alpha reductase inhibitor (5ARI) therapy and to compare the 2 currently ...

JERUSALEM--(BUSINESS WIRE)--Oct. 12, 2015-- Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced the exclusive launch of the generic equivalent to Avodart® (dutasteride) capsules, 0.5 mg, ...

A study comparing the dose-dependent effectiveness of dutasteride, finasteride, and minoxidil—the most common treatments for male pattern baldness—has been released. Taking 0.5 milligrams (mg) of ...

Symptoms of benign prostatic hyperplasia (BPH) affect approximately 50% of men aged 50 years or older, increasing to 90% of men aged 70 years and above. 1 The prevalence of lower urinary tract ...

Dutasteride (Avodart) treatment significantly reduces the relative risk of a prostate cancer (PCa) diagnosis in men with benign prostatic hyperplasia (BPH) undergoing screening with PSA tests and ...

In the treatment of male androgenetic alopecia (AGA), low-dose dutasteride (0.5 mg/d), used off label in the US, tops a ranking of the most commonly used oral and topical agents in a new meta-analysis ...

CHICAGO—Dutasteride lowers the risk of prostate cancer by 23% in men with an increased risk of the malignancy, new findings show. The findings come from the four-year Reduction by Dutasteride of ...

Dongkook Pharmaceutical unveiled an improved new drug that combines two benign prostatic hyperplasia treatments into one, moving to target the benign prostatic hyperplasia treatment market. Dongkook ...